These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7620750)

  • 21. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function.
    O'Keane V; Dinan TG
    Am J Psychiatry; 1991 Aug; 148(8):1009-15. PubMed ID: 1853948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia.
    Mohr P; Horácek J; Motlová L; Libiger J; Czobor P
    Psychopharmacology (Berl); 1999 Jan; 141(3):322-5. PubMed ID: 10027514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.
    Meltzer HY
    Psychopharmacology (Berl); 1989; 99 Suppl():S18-27. PubMed ID: 2682729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response.
    Cleare AJ; Murray RM; O'Keane V
    Biol Psychiatry; 1998 Oct; 44(7):555-61. PubMed ID: 9787879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
    Hasegawa M; Gutierrez-Esteinou R; Way L; Meltzer HY
    J Clin Psychopharmacol; 1993 Dec; 13(6):383-90. PubMed ID: 8120151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of clinical outcome in schizophrenic patients responding to clozapine.
    Mauri MC; Volonteri LS; Dell'Osso B; Regispani F; Papa P; Baldi M; Bareggi SR
    J Clin Psychopharmacol; 2003 Dec; 23(6):660-4. PubMed ID: 14624196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-cycloserine added to clozapine for patients with schizophrenia.
    Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
    Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between clinical improvement and functional gains with clozapine in schizophrenia.
    Lee J; Takeuchi H; Fervaha G; Bhaloo A; Powell V; Remington G
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1622-9. PubMed ID: 25156578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
    Fleischhaker C; Schulz E; Remschmidt H
    Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonergic function in panic disorder: endocrine responses to D-fenfluramine.
    Judd FK; Apostolopoulos M; Burrows GD; Norman TR
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):329-37. PubMed ID: 8208982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine-induced weight gain predicts improvement in psychopathology.
    Meltzer HY; Perry E; Jayathilake K
    Schizophr Res; 2003 Jan; 59(1):19-27. PubMed ID: 12413638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Violence and schizophrenia: clozapine as a specific antiaggressive agent.
    Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC
    Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients.
    Arora RC; Meltzer HY
    Neuropsychopharmacology; 1994 Apr; 10(2):109-14. PubMed ID: 8024672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hormonal response to a d-fenfluramine challenge in trained and sedentary men.
    Strachan AT; Maughan RJ
    Med Sci Sports Exerc; 1999 Apr; 31(4):547-53. PubMed ID: 10211850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers.
    Fishbein DH; Lozovsky D; Jaffe JH
    Biol Psychiatry; 1989 Apr; 25(8):1049-66. PubMed ID: 2720017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects.
    Cleare AJ; Murray RM; O'Keane V
    Neuropsychopharmacology; 1996 May; 14(5):349-54. PubMed ID: 8703303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine and amine responses to D,L-fenfluramine in normal subjects.
    Mitchell PB; Smythe GA
    Psychiatry Res; 1991 Nov; 39(2):141-53. PubMed ID: 1686811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical psychopharmacology: the example of clozapine (Leponex)].
    Péré JJ
    Encephale; 1995 Jun; 21 Spec No 3():9-12. PubMed ID: 7628347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
    Hollander E; Cohen LJ; DeCaria C; Saoud JB; Stein DJ; Cooper TB; Islam NN; Liebowitz MR; Klein DF
    Biol Psychiatry; 1993 Sep; 34(6):407-13. PubMed ID: 8218609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.